Qutipin Tablets - Everything You Need to Know About Generic Quetiapine Fumarate Medication

Qutipin (Generic Quetiapine Fumarate Tablets)
© The Swiss Pharmacy

Qutipin (Generic Quetiapine Fumarate
Tablets) is used for treating schizophrenia,
bipolar disorder, recurrent major depressive
disorder (MDD) and generalised anxiety
disorder (GAD).

Qutipin Tablets are manufactured by
Sun Pharmaceutical Industries Limited,
India in the strengths of 25 mg, 50 mg,
100 mg , 200 mg and 300 mg.

Chemical Structure - Quetiapine Fumarate

The active ingredient contained in Qutipin
tablets is Quetiapine Fumarate.
Each Qutipin tablet contains Quetiapine
Fumarate equivalent to 25 mg, 50 mg, 100 mg,
200 mg or 300 mg of Quetiapine.

Uses of Qutipin 25 mg, 50 mg, 100 mg , 200 mg and 300 mg Tablets:
Qutipin (Generic Quetiapine Fumarate tablets) is used to treat certain
mental / mood conditions (such as schizophrenia, bipolar disorder,
sudden episodes of mania or depression associated with bipolar
disorder). Quetiapine is known as an anti-psychotic drug (atypical type).
This medicine works by helping to restore the balance of certain natural
substances (neurotransmitters) in the brain.
Qutipin can decrease hallucinations and improve your concentration. It
helps you to think more clearly and positively about yourself, feel less
nervous, and take a more active part in everyday life. It may also improve
your mood, sleep, appetite, and energy level. Quetiapine Fumarate
tablets can help prevent severe mood swings or decrease how often mood
swings occur.

Recommended Adult Dosage
For most adult patients, the starting dose of
Qutipin (Generic Quetiapine tablets) for treatment of
Schizophrenia is 25 mg taken twice daily on day 1.
Increase in increments of 25 mg to 50 mg divided two or three
times on Days 2 and 3 to range of 300 to 400 mg by Day 4.
Further adjustments can be made in increments of 25 to 50 mg
twice a day, in intervals of not less than 2 days.
The recommended dose is 150 mg to 750 mg/day and the
maximum dose is 750 mg/day.

Treatment of Bipolar Mania in Adults (Monotherapy or as an
Adjunct to Lithium or Divalproex):
Day 1: Twice daily dosing totaling 100 mg.
Day 2: Twice daily dosing totaling 200 mg.
Day 3: Twice daily dosing totaling 300 mg.Day 4: Twice daily
dosing totaling 400 mg.
Further dosage adjustments up to 800 mg/day by Day 6 should be
in increments of no greater than 200 mg/day.
The recommended dose of Qutipin is 400 mg to 800 mg/day and
the maximum dose is 800 mg/day.

Treatment of Bipolar Depression in Adults:
Qutipin (Generic Quetiapine Fumarate tablets) has to be
administered once daily at bedtime as given below:
Day 1: 50 mg,
Day 2: 100 mg,
Day 3: 200 mg and Day 4: 300 mg
The recommended dose is 300 mg and the maximum dose
is 300 mg/day.

Qutipin Tablets Contraindications
➔
Qutipin is contraindicated in patients with a
known hypersensitivity to Quetiapine Fumarate
or any component of the tablet. Anaphylactic
reactions have been reported in patients treated
with Quetiapine Fumarate.

Storage Instructions
Qutipin (Generic Quetiapine tablets) have to be
stored at controlled room temperature i.e. from
20°C to 25°C (68°F to 77°F) with excursions
permitted between 15° to 30°C (59° to 86°F).
Keep this as well as all other medicines away
from children and pets.

Warnings
Increased Mortality in Elderly Patients with Dementia-
Related Psychosis: Elderly patients with dementia-related
psychosis treated with anti-psychotic drugs are at an
increased risk of death. Quetiapine Fumarate tablets are not
approved for elderly patients with dementia-related
psychosis.
Suicidal Thoughts and Behaviors: Increased risk of
suicidal thoughts and behavior in children, adolescents
and young adults taking antidepressants. Monitor for
worsening and emergence of suicidal thoughts and behaviors.

Warnings
Cerebrovascular Adverse Reactions: Increased incidence of
cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack)
has been seen in elderly patients with dementia-related psychoses treated
with atypical antipsychotic medications.
Neuroleptic Malignant Syndrome (NMS): Manage with immediate
discontinuation and close monitoring
Metabolic Changes: Atypical anti-psychotics have been associated with
metabolic changes. These metabolic changes include hyperglycemia,
dyslipidemia, and weight gain.
Tardive Dyskinesia: Discontinue Qutipin if clinically appropriate.

Warnings
Hypotension: Use with caution in patients with known cardiovascular or
cerebrovascular disease.
Increased Blood Pressure in Children and Adolescents: Monitor blood
pressure at the beginning of, and periodically during treatment in
children and adolescents.
Leukopenia, Neutropenia and Agranulocytosis: Monitor complete blood
count frequently during the first few months of treatment in patients with
a pre-existing low white cell count or a history of leukopenia /
neutropenia and discontinue Qutipin tablets at the first sign of a decline
in WBC in absence of other causative factors.

Warnings
Cataracts: Lens changes have been observed in patients during
long-term quetiapine treatment. Lens examination is recommended
when starting treatment and at 6-month intervals during chronic
treatment.
Anticholinergic (antimuscarinic) Effects: Use with caution with
other anticholinergic drugs and in patients with urinaryretention,
prostatic hypertrophy, constipation, or increased intraocular
pressure.

Possible Side Effects
Most common Quetiapine Fumarate (Qutipin tablets)
side effects with an incidence rate of greater than or
equal to 5% observed in adults include somnolence,
dry mouth, constipation, dizziness, increased appetite,
dyspepsia, weight gain, fatigue, dysarthria, and nasal
congestion.

Possible Side Effects
The following side effects have also been reported with
Quetiapine Fumarate Tablets (Qutipin): nightmares,
hypersensitivity and elevations in serum creatine phosphokinase
(not associated with NMS), galactorrhea, bradycardia (which may
occur at or near initiation of treatment and be associated with
hypotension and/ or syncope) decreased platelets, somnambulism
(and other related events), elevations in gamma-GT levels,
hypothermia, and priapism.

Overdosage
During clinical trials, survival has been reported in acute overdoses of up to 30 grams
of Quetiapine Fumarate Tablets (Qutipin). Most patients who overdosed experienced
no adverse reactions or recovered fully from the reported events. Death has been
reported in a clinical trial following an overdose of 13.6 grams of Quetiapine alone.
In general, reported signs and symptoms were those resulting from an exaggeration
of the medicine’s known pharmacological effects, i.e., drowsiness, sedation,
tachycardia, hypotension, and anti-cholinergic toxicity including coma and delirium.
Patients with pre-existing severe cardiovascular disease may be at an increased risk of
the effects of overdose.
One case, involving an estimated overdose of 9600 mg, was associated with
hypokalemia and first degree heart block. In post-marketing experience, there were
cases reported of QT prolongation with Quetiapine overdose.

Treatment of Overdosage
Establish and maintain an airway and ensure adequate oxygenation and ventilation.
In cases of severe intoxication, the possibility of multiple drug involvement should
be considered, and intensive care procedures are recommended, including
establishing and maintaining a patent airway, ensuring adequate oxygenation and
ventilation, and monitoring and support of the cardiovascular system.
In cases of Quetiapine overdose, refractory hypotension should be treated with
appropriate measures such as intravenous fluids and/or sympathomimetic
agents (adrenaline and dopamine should be avoided, since beta stimulation may
worsen hypotension in the setting of quetiapine-induced alpha blockade).
Appropriate supportive measures are the mainstay of Qutipin (Generic Quetiapine
Fumarate Tablets) overdose management.

Qutipin Tablets During Pregnancy
Quetiapine Fumarate (Qutipin tablets) has been classified by the US FDA as
Pregnancy Category C.
Neonates exposed to antipsychotic medicines during the third trimester of
pregnancy are at risk of experiencing extrapyramidal neurological disturbances
and/or withdrawal symptoms following delivery. There have been post-
market reports of agitation, hypertonia, hypotonia, tremor, somnolence,
respiratory distress, and feeding disorder in these neonates. Following some
pregnancies in which Quetiapine was used, neonatal withdrawal symptoms have
been reported.
There are no adequate and well-controlled studies in pregnant women and
Quetiapine Fumarate (Qutipin tablets) should be used during pregnancy only
if the potential benefit justifies the potential risk to the fetus.

Qutipin Tablets are manufactured by Sun
Pharmaceutical Industries Limited, India.
For More details Click Here

Qutipin Tablets - Everything You Need to Know About Generic Quetiapine Fumarate Medication

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Qutipin Tablets - Everything You Need to Know About Generic Quetiapine Fumarate Medication

Similar to Qutipin Tablets - Everything You Need to Know About Generic Quetiapine Fumarate Medication (20)

More from The Swiss Pharmacy

More from The Swiss Pharmacy (20)

Recently uploaded

Recently uploaded (20)

Qutipin Tablets - Everything You Need to Know About Generic Quetiapine Fumarate Medication